The Laboratory tubes


Orlistat 96829-58-2 Antiobesity Diet supplement

Short Description:

Synonyms: (−)- Tetrahydrolipstatin, Ro-18-0647,

N- Formyl- L-leucine (1S)- 1- [[(2S,3S)- 3- hexyl- 4- oxo- 2- oxetanyl]methyl]dodecyl ester

CAS No.: 96829-58-2

Quality: USP42

Molecular Formula: C29H53NO5

Formula Weight: 495.73

Product Detail

Product Tags

Payment: T/T, L/C
Product Origin: China
Shipping Port: Beijing/Shanghai/Hangzhou
Production capacity: 800kg/month
Order(MOQ): 25kg
Lead Time: 3 Working Days
Storage condition: Stored in cool, dry place, room temperature.
Package material: drum
Package size: 25kg/drum
Safety information: Not dangerous goods



Orlistat is a long-acting and powerful specific gastrointestinal lipase inhibitor. It is white or nearly white powder at room temperature, which insoluble in water, soluble in chloroform, and easily soluble in ethanol. It inactivates the enzyme by forming covalent bonds with the active serine sites of gastric lipase and pancreatic lipase in the stomach and small intestine.

Orlistat is a kind of lipase inhibitor weight-loss drug. It is a hydrated derivative of lipstatin, which can reduce the absorption of food fat and reduce weight. This product has strong and selective inhibition of gastric lipase and pancreatic lipase, has no effect on other digestive enzymes (amylase, trypsin, chymotrypsin) and phospholipase, and does not affect the absorption of carbohydrates, proteins and phospholipids. It inactivates the enzyme mainly through covalent binding with serine residues at the active sites of gastric lipase and pancreatic lipase in the gastrointestinal tract, inhibits the hydrolysis of triacylglycerol, reduces the intake of monoglyceride and free fatty acid, and thus controls body weight. The drug is not absorbed by gastrointestinal tract, and the inhibition of lipase is reversible.

This product also has the function of regulating blood lipids. It can reduce triglyceride and low-density lipoprotein cholesterol in the serum of obese patients and increase the ratio of high-density lipoprotein to low-density lipoprotein.

When orlistat combined with a low calorie diet, it is suitable for the long-term treatment of obese and overweight people, including those who have developed obesity related risk factors. It has long term weight control function such as weight loss, weight maintenance and rebound prevention. The clinical shows obviously that the weight control function is very useful for long term usage when company with meal or after one hour of meal.

Orlistat can reduce the incidence rate of obesity related risk factors and other obesity related diseases, including hypercholesterolemia, type II diabetes, impaired glucose tolerance, hyperinsulinemia, hypertension, and reduce the fat content in organs.

Specification (USP42)




Specific optical rotation -48.0°~-51.0°
Water content ≤0.2%
Related substances I Orlistat related compound A ≤0.2%
Related substances II Orlistat related compound B ≤0.05%
Related substances III


Formylleucine ≤0.2%

Orlistat related compound C ≤0.05%

Orlistat open ring epimer ≤0.2%

D-Leucine orlistat ≤0.2%

Individual unidentified impurity ≤0.1%

Related substances IV

Orlistat related compound D ≤0.2%

Orlistat open ring amide ≤0.1%

Related substances V

Orlistat related compound E ≤0.2%

Total impurities (I to V)


Residual solvents

Methanol ≤0.3%

EtOAc ≤0.5%

n-Heptane ≤0.5%

Residue on ignition


Heavy metals as Pb


Assay by HPLC

98.0%~101.5% (on anhydrous, solvent-free basis)

  • Previous:
  • Next: